RedHill Biopharma (RDHL) Notes Payables (2022)
RedHill Biopharma's (RDHL) quarterly Notes Payables came in at $115.2 million in Q4 2022, up 34.75% quarter-over-quarter from $85.5 million in Q2 2022.
Powered by 
Analysis
RedHill Biopharma (RDHL) Notes Payables (2022) Analysis & Trends
RedHill Biopharma (RDHL) has reported Notes Payables for 1 consecutive years, with $115.2 million the latest figure, recorded in Q4 2022.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $115.2 million in Q4 2022; TTM through Dec 2022 was $115.2 million, a N/A change from a year earlier, with the FY2022 full-year figure at $115.2 million, changed N/A from the prior year.
- Notes Payables was $115.2 million for Q4 2022 at RedHill Biopharma, up from $85.5 million in the prior quarter.
- Over five years, Notes Payables peaked at $115.2 million in Q4 2022 and troughed at $85.5 million in Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - |